Neurocrine Biosciences | NBIX - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
ALKERMES USD 20.89M 8.62M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amgen USD 657M 4M 2026-03
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Cytokinetics USD 33.34M 3M 2026-03
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 240M 15M 2026-03
Halozyme Therapeutics USD 5.51M 597K 2026-03
Incyte USD 569K 13K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 671M 40M 2026-03
Prothena USD 349.89M 347.27M 2026-03
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Repligen USD 5.58M 83K 2026-03
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Teva Pharmaceutical Industries USD 216M 4M 2026-03
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xoma USD 3.4M 150K 2024-06